Intrinsiqq
Nika Pharmaceuticals Inc. logo

Nika Pharmaceuticals Inc. Quality Score

NIKA

Compare
Quality0

Business quality is weak (avg 0/100). Limited dimensions available for this sector.

Broad-market heuristics · Not a buy/sell signal

Business Quality & Capital Allocation

Share Dilution
0/100
166.3%

Heavy dilution above 5%

Capital Structure
0/100
$348662

Positive debt with no FCF to service it

2021
$399
$0.00
2022
$864
$18180
2023
$19596
$203490
2024
$2083
$239164
TTM
$352
$349014
CashDebt
Return on Capital
0/100
-19.6%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Nika Pharmaceuticals (NIKA) quality: score, margins and returns

Nika Pharmaceuticals (NIKA) scores 0/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 3 metrics each scored 0 to 100 and -19.6% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Nika Pharmaceuticals (NIKA) a high-quality business?+

Nika Pharmaceuticals scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 3 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -19.6% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Nika Pharmaceuticals's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from NIKA's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Nika Pharmaceuticals scores well and where it falls behind.

What is Nika Pharmaceuticals's return on invested capital (ROIC)?+

Nika Pharmaceuticals earns about -19.6% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to NIKA's margins and growth on this scorecard to judge durability.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 15 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 10 Nov 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Pharmaceutical Preparations · Pick stocks to compare with NIKA

CompareIntrinsic value
COYACoya Therapeutics Inc.
$2.95-1.01%10
ATOSAtossa Therapeutics Inc
$1.60-8.86%10
XLOXilio Therapeutics, Inc.
$7.56+0.67%50
ABUSArbutus Biopharma Corporation
$4.02-1.23%84
UPBUpstream Bio, Inc.
$1.59-20.50%21
OVIDOvid Therapeutics Inc.
$2.20-5.98%10
LQDALiquidia Corporation
$54.43-3.88%63
PCRXPacira BioSciences Inc.
$36.48+0.00%61

Spot a number that looks wrong? Check it in NIKA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing NIKA

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.